Scancell Holdings plc (SCNLF)

Market Cap	176.99M +38.2%
Revenue (ttm)	6.19M
Net Income	-7.24M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Average Volume	7,038
Open	0.1900
Previous Close	n/a
Day's Range	0.1900 - 0.1900
52-Week Range	0.0980 - 0.1900
Beta	0.33
RSI	55.52
Earnings Date	Jan 29, 2026

About Scancell Holdings

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 60
• Stock Exchange: OTCMKTS
• Ticker Symbol: SCNLF

Financial Performance

Financial numbers in GBP